Ozempic

Ozempic (also known as Semaglutide or GLP-1 agonist) is a therapeutically researched peptide studied for its effects on fat loss, weight loss, cardiovascular. FDA-approved GLP-1 agonist (Ozempic/Wegovy/Rybelsus) with 15-21% weight loss and 20% cardiovascular risk reduction. Nausea common, NAION risk noted.

Semaglutide is an FDA-approved GLP-1 receptor agonist with 94% structural homology to human GLP-1, manufactured by Novo Nordisk as Ozempic (diabetes, 0.25-2mg weekly injection), Wegovy (obesity, up to 2.4mg weekly injection), and Rybelsus (diabetes, 3-14mg daily oral). Activates GLP-1 receptors in the gastrointestinal tract, pancreas, and brain to reduce appetite, delay gastric emptying, increase insulin release, and lower glucagon secretion. STEP trials demonstrated 14.9-17.4% mean weight loss at 68 weeks (2.4mg dose), with 69-79% achieving ≥10% weight loss.

Overview

STEP UP trial showed 20.7% weight loss with 7.2mg dose at 72 weeks.

SELECT cardiovascular outcomes trial showed 20% reduction in major adverse cardiac events (HR 0.80) in patients with obesity and preexisting cardiovascular disease but without diabetes.

FDA-approved March 2024 for reducing cardiovascular death, heart attack, and stroke risk.

Also approved for metabolic-associated steatohepatitis (MASH).

Most common side effects are gastrointestinal (nausea affecting up to 20%, vomiting, diarrhea, constipation), typically transient and mild-to-moderate.

Notable concerns include possible gastroparesis, 85% increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), and thyroid cancer warnings from rodent studies (though human incidence <1%).

Available in both injection (89% bioavailability) and oral forms (0.4-1% bioavailability).

Gradual titration over 12-16 weeks minimizes gastrointestinal side effects.

Mechanism of action

Reduces appetite and slows digestion for 15-21% weight loss. Improves blood sugar control. Lowers heart attack and stroke risk by 20%.

Reported effects

Effects reported in the literature and from preclinical models include:

• In meta-analyses of randomized controlled trials, subcutaneous semaglutide 2.4 mg reduced body weight by about 11.45% versus placebo, and incretin-based therapy within a lifestyle intervention reduced weight by about 10 kg versus control. ^[2][6] Phase II
• Once-daily oral semaglutide produced weight loss superior to placebo in the OASIS trials and comparable to subcutaneous semaglutide, evidence that supported FDA approval of oral Wegovy for chronic weight management. ^[5][7] FDA approved
• Semaglutide is FDA-approved for metabolic dysfunction-associated steatohepatitis in adults with moderate-to-advanced liver fibrosis. ^[3][10] FDA approved
• In placebo-controlled randomized trials, semaglutide reduced liver enzymes and more than doubled the likelihood of steatohepatitis resolution without fibrosis progression, though improvement in fibrosis stage alone was not statistically significant. ^[8] Phase II
• Across four SUSTAIN randomized controlled trials, once-weekly semaglutide 1.0 mg lowered HbA1c by about 0.64 percentage points and body weight by 4.38 kg versus other injectable therapies in type 2 diabetes, with lower hypoglycemia risk than basal insulin. ^[9] Phase II
• Large retrospective cohort studies found semaglutide use associated with an increased risk of non-arteritic anterior ischemic optic neuropathy, with a pooled hazard ratio of about 3.36 at one year in type 2 diabetes and an 85% relative increase versus SGLT2 inhibitor initiators, though absolute risk remained small. ^[4][1] Phase I

Evidence grades: FDA approvedApproved (non-US)Phase IIIPhase IIPhase IPreclinicalAnecdotal

Dosage and administration

Injectable

• Week 1-4: 0.25mg once weekly (subcutaneous)
• Week 5-8: 0.5mg once weekly
• Week 9-12: 1.0mg once weekly
• Week 13+: 2.0mg (Ozempic) or 2.4mg (Wegovy) maximum
• Higher dose: 7.2mg weekly (experimental, 20.7% weight loss)

Oral Rybelsus

• Days 1-30: 3mg daily on empty stomach
• Days 31-60: 7mg daily
• Day 61+: 14mg daily maximum

General

• Take oral form with ≤4oz water, wait 30 min before eating
• Gradual titration over 12-16 weeks reduces GI side effects

Natty status

Ozempic is generally regarded as compatible with the natty designation, particularly when used for therapeutic healing purposes. Opinions vary across natural bodybuilding federations, and athletes who compete should consult the rulebook of their respective sanctioning body.^[11]

Research

The peptide has been the subject of 51 studies and reference works collected on this site. Additional bibliography is in § External links below.

Related compounds

Other peptides in this catalogue with overlapping mechanisms or status:

References

1. ^ NAION vision risk study
2. ^ Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis. Recent review
3. ^ Semaglutide and Its Potential Hepatoprotective Effects Against Acute Drug-Induced Liver Injury. Recent review
4. ^ Semaglutide and risk of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) in type 2 diabetes mellitus: A systematic review and meta-analysis. Recent review
5. ^ A Review of the Oral Semaglutide in Adults with Overweight or Obesity (OASIS) Trials Evaluating Oral Semaglutide (Wegovy) for Chronic Weight Management in Adults With Overweight or Obesity. Recent review
6. ^ GLP-1RA- and Incretin-Based Therapies Within Lifestyle Interventions for Adults with Overweight or Obesity: A Systematic Review and Meta-Analysis. Recent review
7. ^ Evidence-informed guidance for the clinical use of oral semaglutide in obesity management. Recent review
8. ^ Therapeutic role of semaglutide in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis of placebo-controlled trials with GRADE evidence assessment. Recent review
9. ^ Efficacy and Safety of Once-Weekly Semaglutide Versus Basal Insulin and Other GLP-1 Receptor Agonists in Adults With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs: A Systematic Review and Pairwise Meta-Analysis. Recent review
10. ^ Current therapeutic landscape and future treatment perspectives of MASH. Recent review
11. ^ a b World Anti-Doping Agency. (2026). Prohibited List 2026.

External links

• Wikipedia article
• STEP 1 trial weight loss results
• SELECT trial cardiovascular outcomes
• STEP program comprehensive review
• Carpal tunnel surgery outcomes
• StatPearls comprehensive review
• Tirzepatide Versus Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes With Established Cardiovascular Disease: An Indirect Treatment Comparison Meta-Analysis.
• MASLD and MASLD-associated HCC: emerging biomarkers and therapeutic avenues.
• GLP-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease: mechanistic networks and translational implications: a review.
• Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Thyroid Function Tests: A Systematic Review Identifying a Critical Evidence Gap.
• Hair Loss in Patients on Glucagon-Like Peptide 1 Receptor Agonists: Understanding Risks and Managing Outcomes.
• Peri-Procedural Fasting and Gastric Ultrasound Strategies in Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Users: A Systematic Review With Qualitative Synthesis.
• Nutrition-First Support for GLP-1 and Dual Incretin Therapy in Obesity: A Practical Framework for Dietary Management, Symptom Tolerability, and Long-Term Weight Maintenance.
• Swiss obesity clinical practice guidance.
• Semaglutide and Follow-On Peptide Therapeutics: Balancing Innovation, Regulation, and Clinical Outcomes.
• Prospects for Neuroprotective Therapies in Glaucoma: Drug Targets and Emerging Clinical Strategies.
• Quality of life, morbidity, mortality, and long-term prognosis after craniopharyngioma.
• GLP-1 Receptor Agonists and the Ocular Surface: A Narrative Review of Restoration, Remodeling, and Clinical Implications.
• GLP-1 receptor agonists in pediatric obesity and diabetes: a systematic review of efficacy, metabolic effects, and safety.
• Pharmacological mechanisms and clinical impacts of antidiabetic drugs on colorectal cancer risk: a systematic review.
• Glucagonlike Peptide-1 (GLP-1) Receptor Agonists for Cardiometabolic Risk in Severe Mental Illness: A Narrative Review.
• Efficacy and Safety of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Ventricular Arrhythmias and Cardiovascular Events: A Disease-Stratified Network Meta-Analysis.
• Effect of glucagon-like peptide-1 receptor agonists on body weight and urinary albumin-to-creatinine ratio in patients with and without type 2 diabetes: A systematic review and meta-analysis.
• Incretin-Based Therapies in Doxorubicin-Induced Cardiotoxicity: A Systematic Review of GLP-1 and Dual GIP/GLP-1 Agonists.
• GLP-1 Receptor Agonists in Hidradenitis Suppurativa: Time to Treat the Whole Patient.
• GLP-1 and Alcohol-Related Behaviors: Insights From Preclinical Studies.
• Nutritional intake changes during GLP-1 receptor agonist therapy: A systematic review and meta-analysis.
• GLP-1 Receptor Agonists in Cardiac Surgery: From Metabolic Drug to Potential Perioperative Cardioprotective Agent.
• [Safety Management of Incretin-Based Obesity Therapy: Expert Consensus on the Use of Semaglutide and Tirzepatide].
• Glucagon Agonist Therapies and Vision Loss: Balancing Promise with Prudence in India.
• Perioperative management of GLP-1 receptor agonists: a structured narrative review with considerations relevant to neurosurgical patients.
• Semaglutide as a potential neuroprotective agent for neurological and neurodegenerative disorders: Mechanisms, preclinical evidence, and translational challenges and opportunities.
• Liver Organoids: From Disease Modelling to Regenerative Medicine.
• Gastroparesis induced by glucagon-like peptide-1 receptor agonists: A systematic review of clinical features, diagnosis, management, and outcomes.
• Current and forthcoming pharmacotherapies for adolescent obesity: Evidence-based review.
• GLP-1 and dual GIP/GLP-1 receptor agonists' psychopharmacology and putative neuropsychiatric associated effects: a Bradford Hill-informed, systematic, evaluation.
• The liver-gut-brain axis in metabolic dysfunction-associated steatotic liver disease: bidirectional communication, clinical implications, and future perspectives.
• From adiposity to multisystem morbidity: the case for weight loss as disease modification.
• Pharmacological management of obesity: Current landscape and emerging therapies.
• Incretin-Based Therapies as Cardiometabolic Interventions: Outcome Hierarchy, Receptor-Network Pharmacology and Phenotype-Based Clinical Positioning.
• Semaglutide Bioavailability: Limitations, Formulation Innovation and Future Opportunities.
• 10mg Semaglutide — commercial
• Bacteriostatic Water Reconstitution Solution 10ml — commercial